Developed & Manufactured by Biomedica

High quality ELISAs
Developed and manufactured by Biomedica

Featured Products & Promotions

Latest News
  • FGF23 a CV risk factor in former preterm infants
    FGF23 a CV risk factor in former preterm infants
    31 March, 2025
    Preterm birth, defined as birth before 37 weeks of gestation, affects around 10.6% of all live births globally (1). Preterm birth has been identified as a significant factor contributing to long-term cardiovascular morbidity and mortality (2). It is associated with an increased risk of elevated blood pressure, hypertension, type 1 and type 2 diabetes, decreased [...]
  • OSTEOPROTEGERIN increases in infection-induced acute inflammation
    OSTEOPROTEGERIN increases in infection-induced acute inflammation
    24 March, 2025
    Our Osteoprotegerin (OPG) ELISA assay was highlighted in a recent study assessing serum OPG levels during acute inflammatory states induced by a bacterial or viral infection in children. The researchers investigated whether OPG increases during acute inflammatory states and if its levels correlate with other biomarkers. OSTEOPROTEGERIN increases in infection-induced acute inflammation OPG, a key regulator [...]
  • SCLEROSTIN - a biomarker for predicting the onset of frailty
    SCLEROSTIN - a biomarker for predicting the onset of frailty
    18 March, 2025
    The Biomedica SCLEROSTIN ELISA Assay Kit (cat. no. BI-20492) was utilized in a recent publication identifying high-risk frailty groups (full publication).   Sclerostin (SOST) ELISA  (cat. no. BI-20492) Most referenced Sclerostin ELISA in over 300 citations Low sample volume – 20µl / well Validation following international guidelines   SCLEROSTIN - a biomarker for predicting the onset of frailty SCLEROSTIN, [...]
More News
Events
  • Biomedica at Osteologie in Salzburg
    19 June, 2023
    Biomedica features FGF23 ELISA - intact and C-terminal - assays Meet us at the OSTEOLOGIE Conference taking place from 22-24 June 2023 in Salzburg, Austria! We will exhibit at booth # 36 introducing our novel biomarker ELISA assays to investigate bone and cancer induced bone diseases (e.g. Periostin, Semaphorin 4D, LRG, and others). Our focus [...]
  • Biomedica @ Osteologie 2020 in Salzburg
    17 February, 2020
    Meet us at the Osteologie 2020, hosted by the Deutsche Gesellschaft für Endokrinologie and the Österreichische Gesellschaft für Knochen- und Mineralstoffwechsel, taking place from 12-14 March 2020 in Salzburg, Austria! We will exhibit together with our partners Fianostics & TAmiRNA at booth #1. Moreover,  we will present out new VEGF-A ELISA at our poster "Novel VEGF-A ELISA [...]
  • Meet Biomedica at ASN Kidney Week
    7 November, 2019
    Meet us during ASN Kidney Week taking place from November 5-10 2019 in Washington, DC at booth no. 2005 Hosted by the American Society of Nephrology it’s the world’s premier nephrology meeting with more than 13,000 kidney specialists from across the globe. It provides participants with exciting and challenging opportunities to exchange knowledge, learn about [...]
More Events